Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial

Area of Science:

• Neurology
• Clinical Trials
• Outcome Measurement

Background:

• The minimal clinically important difference (MCID) represents the smallest change in outcome with clinical significance.
• Establishing MCID is crucial for interpreting treatment effects in clinical studies.
• The utility of MCID has not been previously defined for myasthenia gravis (MG).

Purpose of the Study:

• To establish minimal clinically important difference (MCID) cut-offs for key outcome measures in myasthenia gravis (MG).
• To assess the clinical relevance of MCID values in distinguishing treatment effects in MG patients.

Main Methods:

• Utilized patient data from a published randomized controlled trial comparing intravenous immunoglobulin (IVIg) and placebo.
• Applied one anchor-based and three distribution-based methods to determine MCID for Quantitative Myasthenia Gravis Score (QMGS), Repetitive Nerve Stimulation (RNS), and Single-Fiber Electromyography (SFEMG).
• Compared patient groups based on achieving change scores exceeding established MCID cut-offs.

Main Results:

• MCID cut-offs for QMGS were determined to be a change of 3.0.
• Anchor-based and 1x Standard Error of Measurement (SEM) MCID cut-offs identified significantly higher responder rates in the IVIg group compared to placebo (58.3% vs. 30.7%, P=0.017).
• MCID methods did not yield meaningful cut-offs for RNS, and anchor-based and effect size MCID cut-offs did not differentiate between IVIg and placebo groups.

Conclusions:

• Quantitative Myasthenia Gravis Score (QMGS) MCID values offer clinically relevant insights and are recommended for use in myasthenia gravis (MG) clinical trials.
• MCID analysis confirms that improvements observed in MG patients receiving IVIg represent clinically meaningful changes.
• The study supports the application of MCID for QMGS in evaluating treatment efficacy in myasthenia gravis.